Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Introducing human adipose-derived mesenchymal stem cells to Avance Ⓡ nerve grafts and NeuraGen Ⓡ nerve guides.

Mathot F., Rbia N., Thaler R., Bishop AT., van Wijnen AJ., Shin AY.

Laboratory Study on Face & Skin, published in J Plast Reconstr Aesthet Surg (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
J Plast Reconstr Aesthet Surg (2020)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
32418840
PMCID
PMC7375015
DOI
10.1016/j.bjps.2020.03.012
Citations
13

Abstract (original English)

Background When direct nerve coaptation is impossible after peripheral nerve injury, autografts, processed allografts, or conduits are used to bridge the nerve gap. The purpose of this study was to examine if human adipose-derived Mesenchymal Stromal/Stem Cells (MSCs) could be introduced to commercially available nerve graft substitutes and to determine cell distribution and the seeding efficiency of a dynamic seeding strategy. Methods MTS assays examined the viability of human MSCs after introduction to the Avance Ⓡ Nerve Graft and the NeuraGen Ⓡ Nerve Guide. MSCs were dynamically seeded on nerve substitutes for either 6, 12, or 24 h. Cell counts, live/dead stains, Hoechst stains, and Scanning Electron Microscopy (SEM) revealed the seeding efficiency and the distribution of MSCs after seeding. Results The viability of MSCs was not affected by nerve substitutes. Dynamic seeding led to uniformly distributed MSCs over the surface of both nerve substitutes and revealed MSCs on the inner surface of the NeuraGen Ⓡ Nerve Guides. The maximal seeding efficiency of NeuraGen Ⓡ Nerve Guides (94%), obtained after 12 h was significantly higher than that of Avance Ⓡ Nerve Grafts (66%) (p = 0.010). Conclusion Human MSCs can be dynamically seeded on Avance Ⓡ Nerve Grafts and NeuraGen Ⓡ Nerve Guides. The optimal seeding duration was 12 h. MSCs were distributed in a uniform fashion on exposed su

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAllograftsBiocompatible MaterialsCell MovementCell SurvivalCollagenHumansMesenchymal Stem Cell TransplantationNerve RegenerationNeurosurgical Procedures

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research